TY - JOUR
T1 - Exploring the Therapeutic Potential of DPP4 Inhibitors in Alzheimer's Disease
T2 - Molecular Insight and Clinical Outcome
AU - Sulangi, Albert Joseph
AU - Lyons, Sarah E
AU - Abdou, Amy A
AU - Patel, Hemangi
AU - Nagliya, Deepika
AU - Joseph, Eileen
AU - Joseph, Carmel
AU - Kumar, Divya
AU - Patel, Shivani
AU - Jinwala, Isha
AU - Parmar, Mayur S
N1 - Copyright © 2024, Sulangi et al.
PY - 2024/10
Y1 - 2024/10
N2 - Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques, neurofibrillary tangles, and cognitive decline. Given the shared neuropathophysiological traits between AD and type 2 diabetes mellitus (T2DM), repurposing antidiabetic medications, such as dipeptidyl peptidase 4 inhibitors (DPP4i), has emerged as a promising therapeutic strategy. This review comprehensively evaluates the preclinical and clinical evidence supporting the potential of DPP4i in preventing or treating AD by modulating Aβ and tau pathology, improving cognitive function, reducing neuroinflammation and oxidative stress, and promoting neuronal survival. The beneficial effects of DPP4i are likely mediated through the modulation of insulin signaling, anti-inflammatory and antioxidant properties, glucagon-like peptide-1 (GLP-1) upregulation, and modulation of the amyloidogenic pathway. While further research is needed to establish their clinical efficacy in AD patients, DPP4i offers a promising avenue for therapeutic intervention for this devastating neurodegenerative disease.
AB - Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques, neurofibrillary tangles, and cognitive decline. Given the shared neuropathophysiological traits between AD and type 2 diabetes mellitus (T2DM), repurposing antidiabetic medications, such as dipeptidyl peptidase 4 inhibitors (DPP4i), has emerged as a promising therapeutic strategy. This review comprehensively evaluates the preclinical and clinical evidence supporting the potential of DPP4i in preventing or treating AD by modulating Aβ and tau pathology, improving cognitive function, reducing neuroinflammation and oxidative stress, and promoting neuronal survival. The beneficial effects of DPP4i are likely mediated through the modulation of insulin signaling, anti-inflammatory and antioxidant properties, glucagon-like peptide-1 (GLP-1) upregulation, and modulation of the amyloidogenic pathway. While further research is needed to establish their clinical efficacy in AD patients, DPP4i offers a promising avenue for therapeutic intervention for this devastating neurodegenerative disease.
U2 - 10.7759/cureus.72648
DO - 10.7759/cureus.72648
M3 - Review article
C2 - 39610591
SN - 2168-8184
VL - 16
SP - e72648
JO - Cureus
JF - Cureus
IS - 10
ER -